iCAD Reports Growing Adoption of Its Xoft Electronic Brachytherapy System by Leading U.S. Regional Hospitals

<0> iCAD Reports Growing Adoption of Its Xoft Electronic Brachytherapy System by Leading U.S. Regional Hospitals </0>

<0> For iCADKevin Burns, 937-431-7967orFor iCAD investor inquiriesLHAAnne Marie Fields, 212-838-3777orFor iCAD media inquiriesSchwartz MSLRachel Gross, 781-684-0770 </0>

iCAD, Inc. (Nasdaq: ICAD), a leading provider of advanced imaging and radiation therapy for the early identification and treatment of cancer, today announced growing demand for and adoption of its for intraoperative radiation therapy (“IORT”). Two new facilities have purchased the Xoft System including Florida Hospital Celebration Health (Celebration, Fla.) and Yuma Regional Medical Center (Yuma, Ariz.).

The Xoft System is FDA-cleared for the treatment of early stage , , and for the treatment of other cancers or conditions where radiation therapy is indicated. As a platform technology, the Xoft System is designed to deliver isotope-free radiation therapy directly to cancer sites during surgery with minimal radiation exposure to surrounding healthy tissue.

“The continued adoption of the Xoft System emphasizes that it is increasingly being used nationwide, in large and small communities, at large and small hospitals and underscores the growing demand for IORT and other electronic brachytherapy treatments. In fact, Xoft System sales in the third quarter of this year equaled total sales in all of fiscal year 2011,” said Ken Ferry, President and CEO of iCAD. “Xoft provides radiation oncologists with an advanced, potentially life-saving radiation therapy option that can dramatically reduce treatment times, while providing more convenient and cosmetically desirable outcomes.”

Florida Hospital Celebration Health is using the Xoft System to deliver IORT for breast cancer. IORT delivers a single, prescribed, targeted dose of isotope-free radiation directly to the tumor cavity during surgery, thereby minimizing radiation to healthy tissue and organs and eliminating the need for a shielded treatment environment. Typical radiation therapy methods for breast cancer include whole breast radiation, which involves daily treatments for five to seven weeks, and partial breast irradiation where 10 treatments are delivered over a period of five days. Florida Hospital Celebration Health is also participating in the company’s 10 year post-market IORT study of the Xoft® Axxent® Electronic Brachytherapy System® for early stage breast cancer.

Yuma Regional Medical Center is also using the Xoft System as an alternative non-surgical procedure for treating patients with squamous and basal cell carcinoma -- the most common forms of skin cancer. Compared to traditional treatment, the Xoft System is a non-invasive procedure that safely delivers radiation to the surface of the skin, while minimizing exposure to surrounding healthy tissue. The current standard of care for these types of skin cancers typically includes several kinds of surgery, topical treatments and radiation therapy. With traditional external beam therapy, patients often receive 30-35 doses over the course of several months. With the Xoft System, treatment can be completed in just 8-10 doses, greatly reducing the number of daily visits or surgical intervention that traditional therapies require.

Xoft® Axxent® Electronic Brachytherapy System® is an isotope-free radiation treatment cleared by the FDA for use anywhere in the body, including for the treatment of early stage breast cancer, endometrial cancer and skin cancer. It utilizes a proprietary miniaturized x-ray as the radiation source that delivers precise treatment directly to cancerous areas while sparing healthy tissue and organs. The Xoft System can be administered as a single course of radiation therapy during surgery in the form of intraoperative radiation therapy (IORT) or in the form of partial breast irradiation (APBI). The Xoft System does not require a shielded environment and the system’s relatively small size and mobility enable it to be used in virtually any clinical setting. A post-market study is underway to assess the safety and efficacy of IORT with the Xoft System. Xoft, Inc. is a wholly owned subsidiary of iCAD, Inc. For more information about Xoft visit .

iCAD is an industry-leading provider of Computer-Aided Detection (CAD) technologies, advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of common cancers. iCAD offers a comprehensive range of high-performance, upgradeable CAD solutions for mammography and advanced image analysis and workflow solutions for Magnetic Resonance Imaging, for breast and prostate cancers and Computed Tomography for colorectal cancer. iCAD’s Xoft System, offers radiation treatment for early-stage breast cancer that can be administered in the form of intraoperative radiation therapy or accelerated partial breast irradiation. The Xoft System is also cleared for the treatment of non-melanoma skin cancer and endometrial cancer. For more information, call (877) iCADnow, or visit .

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.